



3/22/2024

BSWHP Group Choice and Group Value Formulary Changes

The changes below are reflective of BSWHP P&T Committee decisions.

DRUG NAME	FORMULARY CHANGES	Effective Date
Mounjaro (tirzepatide)	Tier 2	PA
Xdemvy (lotilaner)	SP 2	PA

PRODUCT DISCONTINUATIONS

NOTE: These medications will or have been discontinued from the market by the manufacturer. Contact your provider for guidance and next steps.

Drug Name	Current Formulary Tier	Discontinuation Effective Date
Levemir Flexpen	Tier 2	4/1/2024
Levemir 10mL vials	Tier 2	12/31/2024

Novo Nordisk, the manufacturer of Levemir®, announced that LevemirFlexPen® (insulin detemir) and Levemir vials will no longer be available. Novo Nordisk is discontinuing these products because of business reasons and not due to safety or efficacy issues. The supply of Levemir FlexPen is expected to run out by April 2024, but it could run out earlier and supply disruptions could begin as early as January 2024. The vials will be discontinued by December 31, 2024.

Drug Name	Current Formulary Tier	Discontinuation Effective Date
Flovent HFA <i>*brand product discontinued by manufacturer- authorized generic available</i>	Tier 2 QL	12/21/2023

Key

PA= Prior Authorization AL= Age Limit ST= Step Therapy QL=Quantity Limit PV=Preventive drugs NF=Non-formulary Tier 1=preferred generic; Tier 2=preferred brand; Tier 3= Non-preferred brands and generics SP1= specialty preferred generic; SP2= specialty preferred brand; SP3= specialty non-preferred brand; SF=split fill *Changes apply to both formularies if not specified. Removal of drugs from formulary, certain tier changes or added formulary restrictions may not be effective until renewal of your benefits. For more information, call Baylor Scott & White Pharmacy Help Desk at 1-800-728-7947. Drugs may be subject to coverage requirements or limits such as prior authorization. Refer to your formulary or plan documents for additional information. This list does not guarantee coverage.

Flovent Diskus <i>*brand product discontinued by manufacturer- authorized generic available</i>	Tier 2 QL	12/31/2023
On December 31, 2023 , Flovent branded products were discontinued by the manufacturer, GlaxoSmithKline. However, authorized generic (AG) alternatives are available on the Group Value/Group Choice formularies. Covered authorized generic (AG) products will require a new prescription at the pharmacy,		
Drug Name	Current Formulary Tier	Discontinuation Effective Date
GlucaGen HypoKit®	Tier 2	7/1/2024

2024 YEAR- TO- DATE BSWHP FORMULARY CHANGES

DRUG NAME	FORMULARY CHANGES	Effective Date
Litfulo (ritlecitinib)	SP 3 PA	3/1/2024
bromfenac 0.07% ophthalmic solution	Tier 3	1/8/2024
Copaxone injections Glatopa injections	NF; generic (glatiramer) still available on formulary	1/1/2024
Sogroya (somapacitan-beco)	SP 3 PA	1/1/2024
Lupron Depot-PED	SP 2	1/1/2024
entecavir tablets	Tier 1	1/1/2024
Baraclude solution	Tier 3	1/1/2024
Selzentry tablets	NF	1/1/2024
Tarceva tablets	NF	1/1/2024
Nilandron tablets	NF	1/1/2024
Fareston tablets	NF	1/1/2024
Afinitor Dis tablets	NF	1/1/2024
Tykerb tablets	NF	1/1/2024
Sutent capsules	NF	1/1/2024
Targretin capsule, gel	NF	1/1/2024
Apokyn 10mg/mL injection	NF	1/1/2024

Health Maintenance Organization (HMO) products are offered through Scott and White Health Plan dba Baylor Scott & White Health Plan, and Scott & White Care Plans dba Baylor Scott & White Care Plan. Insured PPO and EPO products are offered through Baylor Scott & White Insurance Company. Scott and White Health Plan dba Baylor Scott & White Health Plan serves as a third-party administrator for self-funded employer-sponsored plans. Baylor Scott & White Care Plan and Baylor Scott & White Insurance Company are wholly owned subsidiaries of Scott and White Health Plan. These companies are referred to collectively in this document as Baylor Scott & White Health Plan.

2024 YEAR- TO- DATE BSWHP FORMULARY CHANGES

DRUG NAME	FORMULARY CHANGES	Effective Date
Vyvanse (lisdexamfetamine dimesylate) chewable tablets	AL Added	1/1/2024
Quillivant XR (methylphenidate hcl) suspension 25mg/5mL	AL Added	1/1/2024
Quillichew ER (methylphenidate hcl) chewable tablets	AL Added	1/1/2024
methylphenidate hcl chewable tablets	AL Added	1/1/2024
Indocin suspension	NF	1/1/2024
meloxicam suspension 7.5mg/5mL	NF	1/1/2024
amlodipine/valsartan/hydrochlorothiazide tablets	Tier 3	1/1/2024
protriptyline tablets	Tier 3	1/1/2024
cephalexin capsule 750mg	Tier 3	1/1/2024
levocarnitine 330 mg tablet, solution 1GM/10mL	Tier 1	1/1/2024
cinacalcet tablets	Tier 1	1/1/2024
nebivolol tablets	Tier1	1/1/2024
zolpidem ER tablets	Tier 1	1/1/2024
lacosamide tablets	Tier 1	1/1/2024
febuxostat tablets	Tier 1	1/1/2024
riluzole 50mg tablet	Tier 1	1/1/2024
albendazole 200mg tablet	Tier 1	1/1/2024

Key

PA= Prior Authorization AL= Age Limit ST= Step Therapy QL=Quantity Limit PV=Preventive drugs
 NF=Non-formulary Tier 1=preferred generic; Tier 2=preferred brand; Tier 3= Non-preferred brands and generics SP1= specialty preferred generic; SP2= specialty preferred brand; SP3= specialty non-preferred brand; SF=split fill *Changes apply to both formularies if not specified. Removal of drugs from formulary, certain tier changes or added formulary restrictions may not be effective until renewal of your benefits. For more information, call Baylor Scott & White Pharmacy Help Desk at 1-800-728-7947. Drugs may be subject to coverage requirements or limits such as prior authorization. Refer to your formulary or plan documents for additional information. This list does not guarantee coverage.